Navega Therapeutics has developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific, and long-lasting. Navega Therapeutics has imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way.

Biotechnology

Navega Therapeutics

Ana Moreno

Fernando Aleman

The board of directors at Navega Therapeutics has a history of experience in academia and the pharmaceutical industry. Some members have experience as professors at renowned universities, while others have experience as CEOs and entrepreneurs in the pharmaceutical industry. The board is also educated, with degrees in fields such as biochemistry, electrical engineering, and biomedical engineering.

Board of Directors

About

Team members

Other teams at Navega Therapeutics

Founding Team

Leadership Team